Perceptive Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Perceptive Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-110,728	Closed	-$498K	–	120
2022 Q3	$498K	Hold	110,728	–	–	0.01%	108
2022 Q2	$443K	Sell	110,728 -680,821	-86%	-$3.23M	0.01%	106
2022 Q1	$5.79M	Sell	791,549 -156,932	-17%	-$938K	0.12%	97
2021 Q4	$5.33M	Hold	948,481	–	–	0.08%	115
2021 Q3	$6.07M	Hold	948,481	–	–	0.09%	115
2021 Q2	$8M	Sell	948,481 -1,903,577	-67%	-$15.4M	0.1%	114
2021 Q1	$29.9M	Sell	2,852,058 -1,372,331	-32%	-$19.3M	0.38%	57
2020 Q4	$71.6M	Sell	4,224,389 -41,322	-1%	-$619K	0.77%	36
2020 Q3	$54.7M	Sell	4,265,711 -260,000	-6%	-$3.28M	0.8%	35
2020 Q2	$63.9M	Buy	4,525,711 +1,514,137	+50%	+$19.1M	1.03%	25
2020 Q1	$27.7M	Buy	3,011,574 +90,000	+3%	+$1.16M	0.72%	36
2019 Q4	$43.5M	Buy	2,921,574 +2,255,252	+338%	+$20.1M	0.86%	27
2019 Q3	$4.55M	Buy	+666,322	New	+$6.74M	0.12%	71

Other funds holding PRVB

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Perceptive Advisors's PRVB Position: Q4 2022 in Review

Perceptive Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 110,728 shares — an estimated $498K sold.

Perceptive Advisors first reported a position in PRVB in Q3 2019 and held it in 13 quarters. The position peaked at $71.6M in Q4 2020. 132 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

Perceptive Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Perceptive Advisors sold 110,728 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $498K.
Perceptive Advisors first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
Perceptive Advisors's Provention Bio, Inc. Common Stock position peaked at $71.6M in Q4 2020.
132 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.